| abstract |
The present invention relates to a compound of formula (I) R 1 -QD- (V 1 ) m -R 2 I Or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, D, V 1 , m and R 2 are as defined herein. The present invention also provides a pharmaceutical composition comprising a compound of formula (I) as defined herein or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier, diluent or additive. The present invention also provides a method of inhibiting an MMP-13 enzyme in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention also treats an MMP-13 enzyme mediated disease in a patient comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof, alone or in a pharmaceutical composition. Provide a method. The present invention also relates to cardiac disease, multiple sclerosis, deformity and in a patient comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof, alone or in a pharmaceutical composition Rheumatoid arthritis, arthritis other than degenerative or rheumatoid arthritis, heart failure, inflammatory bowel disease, cardiac dysfunction, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal disease, psoriasis, atherosclerosis And methods of treating diseases such as osteoporosis. The present invention also provides a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with other pharmaceutically active ingredients as defined herein. |